News Center
Learn more about Huizhong
Qunying "decodes" the future trend of veterinary chemicals
- Categories:Media Reports
- Time of issue:2015-09-23
(Summary description)On the afternoon of September 16, the veterinary drug industry development and animal product safety high-level forum on chemical drugs and Chinese veterinary drugs was held in the VIP room on the third floor of the Lihao International Hotel in Luoyang. Li Xiangdong, vice president of the China Veterinary Medicine Association, gave a speech to thank the Veterinary Administration, the Central Supervision Institute, and the Henan Provincial Bureau for their strong support, and the positive responses of the leaders of the backbone enterprises in the veterinary drug industry and all the business representatives present. He pointed out that the center of the conference is "innovation", "technology innovation, management innovation, economic marketing innovation", and innovative concepts and thinking are the original intention to promote the development of the industry. Xu Shixin, Director of the Safety Evaluation Office of China Veterinary Drug Supervision Institute-Decrypting the "Resistance Prohibition Order" Director Xu Shixin first introduced the international standards for the use of antibiotics and enumerated the problems of food safety and environmental pollution caused by several drugs cancelled by the United States and the European Union. It is estimated that 8.424 (16.2×52%) ten thousand tons of antibacterial drugs used in my country’s aquaculture industry in 2013 are used together. my country needs to use 987 g antibacterial drugs per ton of meat produced. The EU standard Denmark uses 40-50 g antibacterial drugs per ton of meat. The difference is nearly 20 times, indicating that there is an excessive use of antibacterial drugs in my country. The Ministry of Agriculture cancelled the four antibacterial drugs of the class of floxacin because they are shared by humans and animals and there is no food safety standard, MRL. He especially emphasized not to misinterpret "anti-antibiotics". It should be understood as "anti-antibiotics" to restrict the use of antibacterial drugs. Antibacterial drugs are not used for food animals and pets can use them. The key is to use them cautiously and rationally. Director Xu Shixin advocates strengthening the research and development of herbivore anti-parasitic drugs, research and development of animal-specific antibacterial drugs, research and development of animal-specific drugs, do not share the definition of new veterinary drugs, drugs that are not available at home and abroad, and extend the protection period of new veterinary drugs: 1. 10 years for Class II drugs, 7 years for Class II drugs, 5 years for preparations, increase innovative scientific research support, and promote GLP/GCP service outsourcing, especially safety evaluation service outsourcing. Professor Zeng Jianguo from Hunan Agricultural University-"Innovation of Chinese Veterinary Medicine and Development of Feeding Plants" The market for veterinary Chinese herbal medicines and Chinese herbal medicine plants in the breeding industry overlap, and attention should be paid to the development of veterinary Chinese medicines and feed plants. Chinese veterinary medicines and human medicines are not intersected, and feed resources are parts that are not used in human medicine or are rarely used. Location. The research and development of Chinese herbal medicine for veterinary use is a necessary means to control the cost of feed additives. Li Chaoyang, Chairman of Shandong Xinde Technology Co., Ltd.-"How to Transform Traditional Veterinary Drug Enterprises under the New Normal" The "new normal" for veterinary drug companies is the further adjustment of the structure of breeding enterprises, the large-scale and intensified breeding. Food safety has become a survival factor for aquaculture companies, and the trough of the aquaculture industry has prolonged. Large veterinary drug companies that have been blessed by the capital market have become more willful, and the two-dimensional code is mandatory. The transformation of veterinary drug companies includes biological products, raw materials, and traditional Chinese medicine extraction with relatively higher entry barriers, product upgrades, improved efficacy of generic drugs, search for new pet and fur markets, shrinking competition areas, and transformation to the Internet (Internet + or + Internet). In addition to the determination and will of the leader, the factors for successful transformation must have a resource base and the establishment of organizational capabilities to adapt to the new business model. Li Shoujun, President of Tianjin Ruipu Biotechnology Co., Ltd.-"Thinking about the transformation and development trend of the veterinary drug industry" Mr. Li first introduced the current situation and challenges faced by my country's veterinary drug companies: ①The veterinary drug companies are small and scattered, with low industrial concentration and overcapacity; ②The evaluation methods and efficiency of veterinar
Qunying "decodes" the future trend of veterinary chemicals
(Summary description)On the afternoon of September 16, the veterinary drug industry development and animal product safety high-level forum on chemical drugs and Chinese veterinary drugs was held in the VIP room on the third floor of the Lihao International Hotel in Luoyang. Li Xiangdong, vice president of the China Veterinary Medicine Association, gave a speech to thank the Veterinary Administration, the Central Supervision Institute, and the Henan Provincial Bureau for their strong support, and the positive responses of the leaders of the backbone enterprises in the veterinary drug industry and all the business representatives present. He pointed out that the center of the conference is "innovation", "technology innovation, management innovation, economic marketing innovation", and innovative concepts and thinking are the original intention to promote the development of the industry.
Xu Shixin, Director of the Safety Evaluation Office of China Veterinary Drug Supervision Institute-Decrypting the "Resistance Prohibition Order"
Director Xu Shixin first introduced the international standards for the use of antibiotics and enumerated the problems of food safety and environmental pollution caused by several drugs cancelled by the United States and the European Union. It is estimated that 8.424 (16.2×52%) ten thousand tons of antibacterial drugs used in my country’s aquaculture industry in 2013 are used together. my country needs to use 987 g antibacterial drugs per ton of meat produced. The EU standard Denmark uses 40-50 g antibacterial drugs per ton of meat. The difference is nearly 20 times, indicating that there is an excessive use of antibacterial drugs in my country. The Ministry of Agriculture cancelled the four antibacterial drugs of the class of floxacin because they are shared by humans and animals and there is no food safety standard, MRL.
He especially emphasized not to misinterpret "anti-antibiotics". It should be understood as "anti-antibiotics" to restrict the use of antibacterial drugs. Antibacterial drugs are not used for food animals and pets can use them. The key is to use them cautiously and rationally.
Director Xu Shixin advocates strengthening the research and development of herbivore anti-parasitic drugs, research and development of animal-specific antibacterial drugs, research and development of animal-specific drugs, do not share the definition of new veterinary drugs, drugs that are not available at home and abroad, and extend the protection period of new veterinary drugs: 1. 10 years for Class II drugs, 7 years for Class II drugs, 5 years for preparations, increase innovative scientific research support, and promote GLP/GCP service outsourcing, especially safety evaluation service outsourcing.
Professor Zeng Jianguo from Hunan Agricultural University-"Innovation of Chinese Veterinary Medicine and Development of Feeding Plants"
The market for veterinary Chinese herbal medicines and Chinese herbal medicine plants in the breeding industry overlap, and attention should be paid to the development of veterinary Chinese medicines and feed plants. Chinese veterinary medicines and human medicines are not intersected, and feed resources are parts that are not used in human medicine or are rarely used. Location. The research and development of Chinese herbal medicine for veterinary use is a necessary means to control the cost of feed additives.
Li Chaoyang, Chairman of Shandong Xinde Technology Co., Ltd.-"How to Transform Traditional Veterinary Drug Enterprises under the New Normal"
The "new normal" for veterinary drug companies is the further adjustment of the structure of breeding enterprises, the large-scale and intensified breeding. Food safety has become a survival factor for aquaculture companies, and the trough of the aquaculture industry has prolonged. Large veterinary drug companies that have been blessed by the capital market have become more willful, and the two-dimensional code is mandatory. The transformation of veterinary drug companies includes biological products, raw materials, and traditional Chinese medicine extraction with relatively higher entry barriers, product upgrades, improved efficacy of generic drugs, search for new pet and fur markets, shrinking competition areas, and transformation to the Internet (Internet + or + Internet). In addition to the determination and will of the leader, the factors for successful transformation must have a resource base and the establishment of organizational capabilities to adapt to the new business model.
Li Shoujun, President of Tianjin Ruipu Biotechnology Co., Ltd.-"Thinking about the transformation and development trend of the veterinary drug industry"
Mr. Li first introduced the current situation and challenges faced by my country's veterinary drug companies: ①The veterinary drug companies are small and scattered, with low industrial concentration and overcapacity; ②The evaluation methods and efficiency of veterinar
- Categories:Media Reports
- Time of issue:2015-09-23 10:20
- Views:
On the afternoon of September 16, the veterinary drug industry development and animal product safety high-level forum on chemical drugs and Chinese veterinary drugs was held in the VIP room on the third floor of the Lihao International Hotel in Luoyang. Li Xiangdong, vice president of the China Veterinary Medicine Association, gave a speech to thank the Veterinary Administration, the Central Supervision Institute, and the Henan Provincial Bureau for their strong support, and the positive responses of the leaders of the backbone enterprises in the veterinary drug industry and all the business representatives present. He pointed out that the center of the conference is "innovation", "technology innovation, management innovation, economic marketing innovation", and innovative concepts and thinking are the original intention to promote the development of the industry.
Xu Shixin, Director of the Safety Evaluation Office of China Veterinary Drug Supervision Institute-Decrypting the "Resistance Prohibition Order"
Director Xu Shixin first introduced the international standards for the use of antibiotics and enumerated the problems of food safety and environmental pollution caused by several drugs cancelled by the United States and the European Union. It is estimated that 8.424 (16.2×52%) ten thousand tons of antibacterial drugs used in my country’s aquaculture industry in 2013 are used together. my country needs to use 987 g antibacterial drugs per ton of meat produced. The EU standard Denmark uses 40-50 g antibacterial drugs per ton of meat. The difference is nearly 20 times, indicating that there is an excessive use of antibacterial drugs in my country. The Ministry of Agriculture cancelled the four antibacterial drugs of the class of floxacin because they are shared by humans and animals and there is no food safety standard, MRL.
He especially emphasized not to misinterpret "anti-antibiotics". It should be understood as "anti-antibiotics" to restrict the use of antibacterial drugs. Antibacterial drugs are not used for food animals and pets can use them. The key is to use them cautiously and rationally.
Director Xu Shixin advocates strengthening the research and development of herbivore anti-parasitic drugs, research and development of animal-specific antibacterial drugs, research and development of animal-specific drugs, do not share the definition of new veterinary drugs, drugs that are not available at home and abroad, and extend the protection period of new veterinary drugs: 1. 10 years for Class II drugs, 7 years for Class II drugs, 5 years for preparations, increase innovative scientific research support, and promote GLP/GCP service outsourcing, especially safety evaluation service outsourcing.
Professor Zeng Jianguo from Hunan Agricultural University-"Innovation of Chinese Veterinary Medicine and Development of Feeding Plants"
The market for veterinary Chinese herbal medicines and Chinese herbal medicine plants in the breeding industry overlap, and attention should be paid to the development of veterinary Chinese medicines and feed plants. Chinese veterinary medicines and human medicines are not intersected, and feed resources are parts that are not used in human medicine or are rarely used. Location. The research and development of Chinese herbal medicine for veterinary use is a necessary means to control the cost of feed additives.
Li Chaoyang, Chairman of Shandong Xinde Technology Co., Ltd.-"How to Transform Traditional Veterinary Drug Enterprises under the New Normal"
The "new normal" for veterinary drug companies is the further adjustment of the structure of breeding enterprises, the large-scale and intensified breeding. Food safety has become a survival factor for aquaculture companies, and the trough of the aquaculture industry has prolonged. Large veterinary drug companies that have been blessed by the capital market have become more willful, and the two-dimensional code is mandatory. The transformation of veterinary drug companies includes biological products, raw materials, and traditional Chinese medicine extraction with relatively higher entry barriers, product upgrades, improved efficacy of generic drugs, search for new pet and fur markets, shrinking competition areas, and transformation to the Internet (Internet + or + Internet). In addition to the determination and will of the leader, the factors for successful transformation must have a resource base and the establishment of organizational capabilities to adapt to the new business model.
Li Shoujun, President of Tianjin Ruipu Biotechnology Co., Ltd.-"Thinking about the transformation and development trend of the veterinary drug industry"
Mr. Li first introduced the current situation and challenges faced by my country's veterinary drug companies: ①The veterinary drug companies are small and scattered, with low industrial concentration and overcapacity; ②The evaluation methods and efficiency of veterinary drug products suitable for modern breeding need to be improved urgently; ③Vicious competition and inferior quality Competition, low R&D aspirations, weak R&D protection, and scattered R&D resources are the main problems that good currencies are subject to inferior currencies; ④Regional oversight is not balanced, management blind spots still exist, and the breeding industry is sluggish, prompting small and medium-sized enterprises and counterfeit veterinary drug companies. Both supply and demand are booming.
After more than one hundred years of development, foreign companies have formed a large-scale and automated breeding model. At the moment when policies are gradually liberalized, if foreign companies enter the domestic market, it is difficult for Chinese companies to hold onto the Chinese market.
Duan Wenlong, Director of the Chemical Drug Evaluation Division of the Veterinary Drug Evaluation Center of the Ministry of Agriculture-"Announcement No. 442 Amendment Prospects and New Veterinary Drug Research and Development Trends"
For veterinary drug review, there are 4 aspects that need to be considered:
①In the 5p veterinary drug and safety assessment, it is safe and controllable to ensure the safety of animal-sourced food and public health; ②Now veterinary drugs should promote the scientific standard and sustainable development of the veterinary drug industry; ③In the veterinary drug approval, the national interest, public interest and user's interest should be guaranteed ④It must be able to withstand the assessment of financial funds.
Five requirements for review activities:
①The review work must be scientific, standardized, professional, and open; ②The review process meets the requirements of openness and transparency; ③The review process can withstand the test of time;
New veterinary drug R&D trends: ①Problems in the process: the industrialization of new veterinary drugs should be formed as soon as possible after the R&D approval; new drug registrants and review should be connected together; new drug R&D should be deeper and clearer; ②The definition of new veterinary drugs should be revised based on international standards ③The research and development of new veterinary drugs is oriented by clinical performance; ④The classification is no longer solely based on the classification of raw materials, but also includes the identification of other aspects, including formulations, to reflect and promote the progress of the industry; ⑤Registration information should include the degree of research and development, technical content, and risk factors Etc.; ⑥ The monitoring period was originally to detect adverse reactions to reflect administrative protection; ⑦ Is the new drug a genuine innovation or a generic innovation.
In response to the future regulatory reform and development trend of the veterinary drug industry, the sub-forums adopted on-site interactive Q&A. Lin Diangong, Director of the Department of Pharmaceutical Administration and Equipment of the Veterinary Administration of the Ministry of Agriculture, Duan Wenlong, Director of the Centralized Drug Evaluation Office of the Veterinary Drug Review of the Ministry of Agriculture, and China Veterinary Drug Supervision Xu Shixin, Director of the Safety Evaluation Office, Zhao Yanling, Director of Hebei Veterinary Drug and Feed Supervision Institute, Ban Fuguo, Director of Henan Veterinary Drug Supervision Institute, Zeng Jianguo, Professor of Henan Agricultural University, Li Shoujun, President of Tianjin Ruipu Biotechnology Co., Ltd., and Shandong Xin Li Chaoyang, Chairman of the Technology Co., Ltd., Wu Liming, Chairman of Baoding Jizhong Pharmaceutical Co., Ltd., Hu Wei, General Manager of Luoyang Huizhong Biotechnology Co., Ltd., Wei Lijuan, Technical Director of Hebei Yuanzheng Pharmaceutical Co., Ltd. President Jiang Housheng of Taier Technology Co., Ltd. presided over. During the interaction, Director Lin Diansheng revealed that the Veterinary Bureau is drafting guidelines for the pet industry, and this opinion will be more strictly regulated; Director Duan Wenlong revealed that the new pet product approval management measures are expected to be in Implemented at the end of this year.
Scan the QR code to read on your phone
Recommended news
ABOUT HUIZHONG
Huizhong Biotech
Upright and Stable Operation
Innovation Creates the Future
Luoyang Huizhong Biotech Co., Ltd. is a private high-tech enterprise located in Luoyang City Luolong High-tech Industrial Development Zone. Based on the successful operation of Huizhong Veterinary Medicine for 20 years, the company adhere to high starting point and high standard new veterinary vaccines research and development, production, and promotion.
Contact Us
Add:No. 25 Yuwenkai Street, Luolong District, Luoyang City, Henan Province
Tel:0379-69981188
Fax:0379-69981166
Email:17737969048@163.com
Mobile terminal
WeChat public account